Uni-Bio Science Group Ltd. has announced a new strategic direction focused on becoming a global leader in regenerative medicine. The company plans to shift its focus from stable growth to innovation-driven development, leveraging next-generation synthetic biology and complex peptides as core technological platforms. Uni-Bio aims to enhance collaboration across industry, academia, research, and medicine, and to establish international technology partnerships and co-develop a capital ecosystem. The company is seeking deeper synergies with global research institutions, clinical experts, industry partners, and investors. Additionally, Uni-Bio has launched new Chinese and English official websites to improve transparency and communication regarding its research and development progress, pipeline in regenerative medicine, and partnership opportunities. The group is also actively advancing the U.S. FDA application for its osteoporosis treatment Uni-PTH and has entered a strategic collaboration for international market expansion.